Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623424 · ClinicalTrials.gov registry record
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
A clinical trial of Stem Cell Transplant Complications, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- 255
- Enrollment target
- 1
- Study location
NCT04623424: Recruiting study of Stem Cell Transplant Complications, sponsored by Henry Ford Health System.
NCT04623424 is a study of Stem Cell Transplant Complications that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 255 participants, above the 169-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (51% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04623424, a study of Stem Cell Transplant Complications, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- 255 participants
- Enrollment target
- 1
- Study location
Study Summary
In this prospective study, the primary objective will be to investigate the association between the use of antibiotics administered during the admission period of Stem cell transplant (SCT) and the rate of overall change in microbiota composition across adjacent samples in time.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST intestinal microbiota
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2028-11-03 |
What NCT04623424 shows while recruiting
NCT04623424 is an observational study that tracks outcomes without assigning an intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 169-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (51% higher).
The record links to 1 condition, with Stem Cell Transplant Complications appearing as the primary indexed condition, and to 1 intervention - of which intestinal microbiota is the first listed.
NCT04623424 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04623424 about?
NCT04623424 is a clinical study titled "Intestinal Microbiota in Stem Cell Transplant Transplant Admission". In this prospective study, the primary objective will be to investigate the association between the use of antibiotics administered during the admission period of Stem cell transplant (SCT) and the rate of overall change in microbiota composition across adjacent samples in time.
What is the current status of trial NCT04623424?
This trial is currently recruiting. The enrollment target is 255 participants. The study started on 2020-11-03. Estimated completion is 2028-11-03.
What conditions does trial NCT04623424 study?
This clinical trial studies the following conditions: Stem Cell Transplant Complications.
What interventions are being tested in trial NCT04623424?
The interventions under investigation include: intestinal microbiota (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04623424?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04623424 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplant Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04623424's enrollment target sits among peer trials
255 4th of 15 higher than 12 of 15 other Stem Cell Transplant Complications trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stem Cell Transplant Complications trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
RECRUITING · Phase 2
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
RECRUITING · Phase 3
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
- NCT05616130 · 255 participants
Pathological Myeloid Activation After Sepsis and Trauma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI